Ginkgo Bioworks Holdings (DNA) Equity Average (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Equity Average of $475.9 million for Q1 2026, down 30.2% year-on-year from $681.7 million in Q1 2025, and down 10.92% on a QoQ basis from $534.2 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Equity Average data on file, last reported at $475.9 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 30.2% year-over-year to $475.9 million; the trailing twelve-month figure through Mar 2026 stood at $475.9 million (down 30.2% YoY), and the FY2025 full-year result was $612.3 million, down 32.46% from the prior year.
- Equity Average for Q1 2026 stood at $475.9 million, down from $534.2 million in the prior quarter.
- Across five years, Equity Average topped out at $1.7 billion in Q1 2023 and bottomed at $475.9 million in Q1 2026.
- The 5-year median for Equity Average is $1.0 billion (2024), against an average of $1.1 billion.
- The widest annual swing landed in 2022, when Equity Average surged 324.77%; it then slumped 41.49% in 2024.
- A 5-year view of Equity Average shows it stood at $1.6 billion in 2022, then decreased by 26.11% to $1.2 billion in 2023, then slumped by 35.57% to $757.0 million in 2024, then fell by 29.43% to $534.2 million in 2025, then dropped by 10.92% to $475.9 million in 2026.
- The last three Equity Average figures came in at $475.9 million (Q1 2026), $534.2 million (Q4 2025), and $586.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | 475.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 475.87 Mn |
| Dec 31, 2025 | 534.19 Mn |
| Sep 30, 2025 | 586.37 Mn |
| Jun 30, 2025 | 630.19 Mn |
| Mar 31, 2025 | 681.74 Mn |
| Dec 31, 2024 | 757.00 Mn |
| Sep 30, 2024 | 815.51 Mn |
| Jun 30, 2024 | 910.17 Mn |
| Mar 31, 2024 | 1.04 Bn |
| Dec 31, 2023 | 1.17 Bn |
| Sep 30, 2023 | 1.38 Bn |
| Jun 30, 2023 | 1.56 Bn |
| Mar 31, 2023 | 1.67 Bn |
| Dec 31, 2022 | 1.59 Bn |
| Sep 30, 2022 | 1.51 Bn |
| Jun 30, 2022 | 1.60 Bn |
| Mar 31, 2022 | 1.59 Bn |
| Dec 31, 2021 | 1.59 Bn |
| Sep 30, 2021 | 986.88 Mn |
| Jun 30, 2021 | 375.68 Mn |
| Mar 31, 2021 | 432.81 Mn |
| Dec 31, 2020 | 493.19 Mn |
| Sep 30, 2020 | 509.09 Mn |